The blood–brain barrier severely limits therapeutic access to the brain. A platform uses the transferrin receptor (TfR) on brain endothelial cells to shuttle a therapeutic antibody that targets amyloid-β (Aβ) into mouse brain. The TfR-mediated transport increases antibody penetration and distributes the therapeutic throughout brain tissue. Compared with unshuttled Aβ-targeting antibodies, the TfR-shuttled antibody shows improved brain distribution and an enhanced safety profile in mice. The approach leverages endogenous receptor-mediated transcytosis pathways to overcome vascular restriction and to reduce peripheral exposure. This method supports more effective delivery of large biologics to the CNS.
"The blood-brain barrier represents a considerable hurdle for drug delivery to the brain. A new study in Science describes a platform that uses the transferrin receptor (TfR) expressed on brain endothelial cells to transport a therapeutic antibody targeting amyloid-beta (Aβ) into the mouse brain. This approach showed improved brain distribution and safety compared with unshuttled Aβ-targeting antibodies."
"A new study in Science describes a platform that uses the transferrin receptor (TfR) expressed on brain endothelial cells to transport a therapeutic antibody targeting amyloid-beta (Aβ) into the mouse brain. This approach showed improved brain distribution and safety compared with unshuttled Aβ-targeting antibodies."
Read at Nature
Unable to calculate read time
Collection
[
|
...
]